Navigation Links
Post-Chemo Treatment May Boost Lung Cancer Survival
Date:5/20/2010

Study finds some benefit with erlotinib for people with non-small-cell form of disease

THURSDAY, May 20 (HealthDay News) -- Among people with non-small-cell lung cancer, treatment with the drug erlotinib (Tarceva) after chemotherapy appears to slightly boost survival rates, a new study suggests.

Non-small-cell lung cancer makes up about 85 percent of lung cancer cases. About half the time, people have advanced disease when diagnosed and are treated solely with chemotherapy, usually platinum-based chemo. But chemotherapy only boosts survival by eight to 10 months, the study authors noted.

The study findings, which support the use of erlotinib as a "maintenance" treatment, are based on research by Dr. Federico Cappuzzo of the Civil Hospital of Livorno in Italy and his colleagues. The researchers tested the drug in 889 people who'd had chemotherapy and whose disease had not gotten worse. They were randomly assigned to take erlotinib an inactive placebo.

According to the study, published online May 19 in The Lancet Oncology, the drug improved overall survival, compared with the placebo (12 months versus 11 months). The length of time without the disease progressing also was somewhat better for those who took the drug: 12 rather than 11 weeks. Most people tolerated the drug well, with skin rash and diarrhea being the most common side effect, the study found, but serious side effects affected 11 percent of those who took the drug, compared with 8 percent of those taking the placebo.

"The acceptable tolerability profile of erlotinib, together with proven efficacy in all patient subgroups and oral dosing, distinguishes erlotinib from other agents in this setting and could provide greater treatment choice for clinicians," the researchers concluded.

More information

The American Cancer Society has details about non-small-cell lung cancer.



-- Randy Dotinga



SOURCE: The Lancet Oncology, news release, May 19, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Book Delivers Latest ADHD Research, Treatments & Results
2. Early Treatment With Clot-Busting Drug Best After Stroke
3. CIGNA and Cancer Treatment Centers of America Reach New Agreement
4. New hope for better treatment for a rising cancer
5. Passages to Recovery Outdoor Addiction Treatment Program Achieves Joint Commission Accreditation
6. New technology aids in prostate cancer treatment
7. Impotence Drugs May Aid Brain Tumor Treatment
8. Self-directed behavioral IBS treatment rapidly relieves even the most severe symptoms
9. Researchers discover new way to rescue treatment sensitivity of breast cancer cells
10. Smarter use of existing treatment helps dramatically boost survival of young AML patients
11. Med Spa Treatments Become More Popular as Unemployment Rates Climb
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 2016 , ... The Behavioral Health Center of Excellence (BHCOE) ... as a top behavioral service provider in the country. The award celebrates exceptional ... and qualifications, and consumer satisfaction. These areas are measured via a wide-ranging audit, ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... thrilled to formally announce its Not a Moment to Lose fundraising campaign. As ... rally supporters dedicated to declaring victory over cancer. The campaign aims to raise ...
(Date:12/6/2016)... ... December 06, 2016 , ... Gateway Analytical, one of ... particle counting and sizing services for USP 788 and 789 particulate standards compliance. ... as a response to the needs of pharmaceutical and medical device manufacturers, who ...
(Date:12/6/2016)... ... 06, 2016 , ... METTLER TOLEDO has launched its online ... white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user ... documents, webinars and videos available online, visit the METTLER TOLEDO Expertise Library ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder ... one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016  BioAtla, ... the development of Conditionally Active Biologic (CAB) ... Beijing Sinobioway Group Company, Limited (Sinobioway) selected ... development.  The specific program candidates and the ... 2015, BioAtla and Sinobioway entered into a ...
(Date:12/5/2016)... 2016 United Kingdom Ophthalmic Diagnostic Equipment ... new report, "United Kingdom Ophthalmic Diagnostic Equipment Market ... the United Kingdom Ophthalmic Diagnostic Equipment market. The ... volume (in units) and average prices (USD) within ... Ultrasound Imaging Systems, Corneal Topography Systems, Ophthalmoscopes, Perimeters, ...
(Date:12/5/2016)... INTRODUCTION Since the ... as a crucial class of pharmacological interventions responsible ... are also used for prophylactic purposes in patients ... patients undergoing chemotherapy). However, the inappropriate use of ... rapidly accelerated an evolutionary response of antibiotic drug ...
Breaking Medicine Technology: